Topic resource collection
Approved comparison material connected to this topic.
15 resourcesRead both sides
The table below summarizes the three major developments in peptide news November 2026, including regulatory changes, metabolic peptide advances, and neuroprotective breakthroughs. FDA 503B Guidance (Nov 14) Formalized quality sta…
September 2026 peptide news included significant formulation breakthroughs, particularly oral bioavailability improvements and novel delivery mechanisms. The table below compares leading peptide compounds by delivery method, bioa…
The following table summarises the three major categories of peptide-related developments reported in April 2026, comparing regulatory changes, clinical trial outcomes, and supply chain shifts across key metrics. Regulatory (FDA …
Purity Standard ≥95% via HPLC; ≥98% for Real Peptides products ≥98% via HPLC + USP monograph compliance Research: HPLC certificate sufficient; Clinical: Full USP validation required In vitro studies, animal models, mechanism rese…
Metabolic & Obesity Research Survodutide, mazdutide, and retatrutide Phase 3 results published; FDA provisional approval expected Q2 2027 GLP-1 agonists, dual- and triple-receptor agonists, glucagon analogs Immediate. Peptides tr…
Peptide news July 2026 introduced multiple compounds with overlapping but distinct mechanisms. Understanding which molecule fits specific research applications requires comparing receptor targets, half-life profiles, and document…
The following table summarizes the three major peptide research breakthroughs reported in March 2026, comparing their mechanisms, clinical or experimental endpoints, and current research availability. GLP-1/GIP Dual Agonists (Tir…
The October 2026 peptide landscape includes multiple metabolic peptides with overlapping but distinct mechanisms. This comparison synthesizes clinical trial data published or updated in October 2026. Retatrutide 12mg GLP-1 + GIP …
The three major trials released in May 2026. TRIUMPH-2 (retatrutide), SYNCHRONIZE-NASH (survodutide), and MATTERHORN (mazdutide). Represent distinct receptor agonist strategies with different primary endpoints. This comparison cl…
Semax and Selank share a nasal-spray format and Russian research origin but are structurally unrelated: Semax is studied for cognition and neuroprotection, Selank for anxiety and immune-linked effects. For research use only.
AHK-Cu (Copper Tripeptide-3) and GHK-Cu (Copper Tripeptide-1) are structurally distinct copper peptides — GHK-Cu has the broader hair/skin literature, AHK-Cu is studied more narrowly for follicular vascularization, and both remai…
BPC-157 promotes gut/organ repair. TB-500 leans connective tissue and cardiac repair. Neither has strong human data, and both are banned in drug-tested sport.
Format dictates GHK-Cu delivery, target access, and which studies apply. How topical, nasal, sublingual, and injectable formats compare for research design. For research use only.
Understanding the differences between lyophilized (freeze-dried) and non-lyophilized peptide formats, their stability profiles, and when each form is preferred for research applications.
Triple GLP-1/GIP/Glucagon Agonists Retatrutide, Mazdutide Multi-receptor activation: GLP-1 (satiety), GIP (insulin secretion), glucagon (lipolysis, thermogenesis) TRIUMPH-1 Phase III: 24.2% weight loss at 48 weeks; FDA Priority R…